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ABSTRACT 
 
 
 
 
Diabetes is a metabolic disease which is very common in today’s generation and patient 
suffering from diabetes either has faulty cells which do not respond to insulin properly or has 
inadequate production of insulin in the body due to which glucose level in the blood rises which 
leads to frequent urination, Patient becomes increasingly thirsty (Polidipsia) and hungry 
(polyphagia ).  There are mainly three types of diabetes TYPE1, TYPE2 and GESTATIONAL 
but type is the most common one. In type 2 Diabetes Mellitus patient’s body does not produce 
enough insulin for proper functioning or the cells do not react to the insulin properly. Obese and 
overweight people have more chances of developing type2 diabetes mellitus. According to age 
also risk of Diabetes Mellitus increases. As we get older chances of having type 2 diabetes 
mellitus increases. Researchers from university of eidenburgh have reported that men whose 
testerone levels are low have higher chances of having Diabetes Mellitus Type 2 because 
Testerone levels are directly linked to insulin resistance. Approximately 90% of all the cases 
worldwide are of Diabetes Mellitus type2. 
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INTRODUCTION 
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1. INTRODUCTION 
 
 
Diabetes Mellitus is a metabolic disease in which a person has high level of blood sugar. Many 
symptoms   are produced due to high blood sugar like Increased thrust, frequent urination, 
Increased Hunger .  diabetes can cause many complications like nonketotic hypersmolar 
coma and diabetic ketoacidosis, Heart disease, Kidney failure if it is not treated on time [1]. 
Main cause of high blood sugar level is alpha glucosidase enzyme, it breaks down starch and 
disaccharide to glucose [2]. Maltase is also a similar kind of enzyme that cleaves maltose is 
functionally equivalent. Alpha Glycosidase inhibitors are anti-diabetic drugs used for diabetes 
mellitus type 2 which prevents the digestion of carbohydrate . 
There are three types of diabetes type1, type2 and gestational diabetes. In Type1 Diabetes 
 
body does not produce insulin, It is characterized by loss of the insulin-producing beta cells of 
the islets of Langerhans in the pancreas which leads to insulin deficiency. The majority of type 1 
diabetes is of the immune-mediated nature, in which a T-cell-mediated autoimmune attack 
leads to the loss of beta cells and thus insulin. In type2 cells fail to use insulin properly and in 
Gestational Diabetes Pregnant women are highly affected because women have high levels of 
glucose in their blood and they are unable to produce sufficient insulin to transport whole 
glucose into their cells which results in progressively rising levels of glucose [3]. 
 
Alpha Glucosidase leads to high production of glucose in the body hence by targeting this 
enzyme and identifying its inhibitors excess glucose production can be controlled [4]. 
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Figure1: Alpha-Glucosidase catalyzed action. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 :       classification of diabetes mellitus. 
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2. REVIEW OF LITERATURE 
 
 
 
2.1. Diabetes Mellitus 
 
 
 
Diabetes Mellitus is a metabolism disorder which means most of the food which we consume 
for energy is broken down into glucose and glucose is a form of sugar in the blood, Glucose is 
principle source of fuel of our body but it cannot enter our cells without insulin being present. 
Insulin is a hormone which is produced by the pancreas [5]. After taking food, Pancreas 
automatically releases an adequate quantity of insulin so that glucose present in blood can move 
to cells, as soon as it enters the cells blood-glucose level drops. 
A person with diabetes has the condition called hyperglycemia in which quantity of glucose in 
blood is too elevated and the reason is either the body does not produce enough insulin, produces 
no insulin or cells do not respond properly to the insulin. In this situation instead of providing 
essential energy glucose passes out of the body in urine [6]. 
Diabetes mellitus has been associated with depression, it is more common in adults with type 2 
diabetes mellitus (T2DM) as compared to those without. Both micro- and macro vascular 
diabetic complications are associated with depression .Less glycemic control in T2DM patients 
could lead to more complications of diabetes and such patients are more likely to develop 
depression. More research is required in this area to determine the exact relationship between 
depression and T2DM and to unfold the mystery of mechanism behind this. The number of 
adults with diabetes worldwide is predicted to almost double over the next 25 years, from 
approximately 171 million in 2000 to 366 million by 2030. Diabetes mellitus is rapidly getting 
close to what could be referred to as epidemic proportions.  In every 10 seconds, diabetes causes 
 
 
5 | P a g e 
one death. It is also associated with cardiovascular disease (CVD), adult-onset blindness as as 
well as  and renal failure. Nonetheless, diabetes can be kept under  control through small 
investments, and can be  wholly prevented through  interventions that are  simple  and cost- 
effective. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 : Diabetes distribution among population. 
 
 
 
 
 
 
 
 
 
 
 
2.1.1. SYMPTOMS OF DIABETES 
 
•    Polydipsia 
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•    polyphegia 
 
•    Lethargy 
 
•    Stupor 
 
•    Blurred vision 
 
•    Smell of acetone 
 
•    Weight loss 
 
•    Kussmaul breathing (hyper-ventillation) 
 
•    Nausea 
 
•    Vomiting 
 
•    Abdominal pain 
 
 
 
 
 
 
 
 
 
 
 
2.1.2. CAUSES OF DIABETES 
 
Lifestyle and environmental factors are 2 major factors responsible for diabetes especially in 
adults but main causes are listed below. 
 
 Inherited Traits or hereditary : A person can inherit diabetes due to some genes which passes 
from one generation to another but  it depends upon closeness of blood relationship if mother is 
diabetic, the risk is 2 to 3% and if father is diabetic the risk is more than the previous case and if 
both the parents are diabetic then the child has much greater risk for diabetes. 
     Age : Increased age gives more possibility than in younger age. Diabetes may occur at any age, 
 
but 80% of cases occur after 50 year, incidences increase with the age factor. 
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  Malnutrition Related Diabetes (poor diet) : low protein and fiber intake, Improper nutrition, high 
intake of refined products can be the major reasons for developing diabetes. 
  Fat and obesity Distribution : overweight means increased insulin resistance means if body fat is 
more than 30%, BMI 25+, waist grith 40 inches in males or 35 inches in women. 
 Sedentary Lifestyle : People with this type of lifestyle are more prone to diabetes, compared to 
those who exercise regularly. 
 Stress : emotional disturbance or physical injury  is frequently blamed as the initial cause of the 
disease. 
     Drug Induced: Olanzapine (Zyprexa), risperidone (Risperdal), quetiapine (Seroquel),ziprasidone 
 
(Geodon), Clozapine (Clozaril) can induce this lethal disease. 
 
 Infection :  Some  of  the  strephylococci is  supposed  to  be  responsible  factor  for  infection  in 
pancreas. 
 Sex : Diabetes is commonly seen in elderly  males and females but  those females with multiple 
pregnancy or suffering from (PCOS) Polycystic Ovarian Syndrome are more vulnerable. 
 Hypertension: According to mant studies it has been reported that  there is direct relation between 
high systolic pressure and diabetes. 
 Lipoproteins and serum lipids: High triglyceride and cholesterol level in the blood is related to high 
blood sugars but in some cases  studies had suggested  that risk is involved even with low HDL 
levels in circulating blood. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.3 ROLE  OF ALPHA-GLUCOSIDASE IN DIABETES 
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In Diabetes Mellitus glucose level in blood rises extremely which causes many adverse effects to 
patient. Alpha Glucosidase is an enzyme which is the main reason for this and hence by using its 
inhibitors we can inhibit the excess glucose production. 
 
 
 
 
Figure 4: Pathway of alpha-glucosidase 
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 Figure 5 : 
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2.2 ROLE  OF ALPHA-GLUCOSIDASE INHIBITORS IN DIABETES MELLITUS 
 
 
 
Alpha-Glucosidase inhibitors play a key role in suppressing elevated glucose concentration in 
blood. Good inhibitors are acarbose, voglibose and migilol which are already available in the 
market and use as drugs. 
 
 
 
 
 
 
 
Figure 6 : Role of Alpha Glucosidase inhibitors. 
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3  OBJECTIVES 
 
 
   Screening of synthetic as well as natural compounds to find a novel drug. 
 
 
     Finding the best drug based on binding energy calculations, toxicity prediction and drug likeness. 
 
 
    Identification of active sites in the target enzyme. 
 
 
    Screening of ligands based on their binding at the active site of target enzyme. 
 
 
     Docking of selected ligand and target to determine the binding energy of interaction.. 
 
 
    Analysis of the docking result for identification of best inhibitor  molecule. 
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PLAN OF WORK 
 
 
 
 
    . Selection of the target enzyme based on its metabolic pathways. 
 
    Finding active sites of target enzyme by uniprot as well as castp. 
 
 Selection of appropriate inhibitors from natural molecule database as well as synthetic 
compounds. 
    Docking of ligands and target enzyme by using ATODOCK. 
 
    Selection of best inhibitor on the basis of binding energy. 
 
    Toxicity prediction of the best inhibitor so that we can propose it as a drug to be used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
 
MATERIALS AND METHODS 
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5 MATERIALS AND METHODS 
 
 
 
5.1   MATERIALS: 
 
 
•          Requirement of files: 
 
 
 
•    PDB file of Alpha-Glucosidase (PDB ID 2QMJ). 
 
•    PDB file of ligand molecule. \ 
 
•    PDBQT file of ligand and Alpha-Glucosidase 
 
 
 
 
 
 
•        Requirement of Software’s: 
 
 
•   Autodock 
 
•   Pro-drg 
 
•    Argus Lab 
 
•   chimera 
 
 
 
 
 
 
•          Requirement of online server’s: 
 

•     http://www.rcsb.org/ 
 
•     http://www.swissdock.ch/ 
 
•     http://www.uniprot.org/ 
 
•     http://davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg 
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METHODS: 
 
In this Insilco based screening, we have selected Alpha-Glucosidase (PDB ID 2QMJ) which 
breaks down starch and disaccharides to glucose and is responsible for main cause Diabetes. 
 
5.2 Preparation of protein molecule: 
 
Alpha-Glucosidase   (PDB   ID2QMJ)   were   downloaded   from   the   protein   data   bank 
 
(http://www.rcsb.org/pdb) [7], already complexed with the inhibitors. Alpha-Glucosidase is 
human 
 
intestinal maltase-glucoamylase made up of single chain A, 870  long amino acid sequence 
protein. Then this PDB file of Alpha-Glucosidase is opened in chimera 1.6.1 where the inhibitor 
molecule that is complexed with Alpha Glocosidase was removed and we get pure form of alpha 
glycosidase. Then pdb file of this molecule was saved for further use in docking process. 
 
 
 
Selection of ligand molecule: 
 
Ligand molecule was selected from (http://www.msdiscovery.com/natprod.html) containing 800 
 
chemical entities obtained from different natural sources and from available drugs in the market.. 
 
 
 
 
5.2.1 Docking: 
 
In this study we have used MGL TOOLS for docking. 
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5.2.2 Inputs 
 
In Autodock server we have to follow some steps to access docking. The sample files can be 
directly uploaded into the form [8]. 
 
 
 
 
 
Figure 7: Autodock 
 
 
 
 
 
 
 
5.2.3 Selection of target protein: 
 
Target protein was loaded by just providing the PDB ID or protein FASTA sequence or by URL 
 
or by uploading as the PDB files that was saved earlier after processed in chimera. Before 
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uploading the target protein we have to take care of Active sites which we can get from uniprot 
or CASTP [9] [10]. 
 
 
 
5.2.4 Selection of ligand molecule: 
 
Ligand molecule can be selected by uploading the PDB file of ligand molecule. 
 
 
 
 
5.2.5 Outputs: 
 
When docking is completed then we get a text file of docking energy,according to the value we 
can find whether ligand chosen can be a effective inhibitor or not. 
 
 
 
5.2.6 Analysis and active site prediction: 
 
The active site/ binding site of Alpha-Glucosidase was predicted by using uniprot or CASTP [8]. 
 
 
 
Figure 8 : Prediction of active sites in uniprot. 
 
 
 
 
 
 
 
5.2.7 Structural analysis of docked molecule: 
 
Binding energy obtained after docking can be compared with already available drug in the 
market and we can carry out further tests to check its toxicity and drug likeliness. 
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mode |   affinity | dist from best mode 
| (kcal/mol) | rmsd l.b.| rmsd u.b. 
-----+------------+----------+---------- 
1 -7.4 0.000 0.000 
2 -6.8 2.595 3.285 
3 -6.3 2.672 5.373 
4 -6.3 3.615 5.852 
5 -6.3 2.453 5.248 
6 -6.1 2.465 4.187 
7 -5.9 1.589 2.143 
8 -5.8 2.609 4.884 
9 -5.6 2.586 4.343 
Writing output ... done.  
 
Figure 9: Binding energy result. 
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METHYL 
 
 
 
 
 
 
 
 
    RESULTS 
 
 
 
In this study Alpha Glucosidase (PDB ID 2QMJ) was docked with 80 different natural as well as 
synthetic compounds. Based on the binding energy we got the best inhibitor of Alpha- 
Glucosidase. 
 
 
 
 
 
 
6.1. BEST POTENTIAL INHIBITORS BASED ON ENERGY CALCULATIONS OF 
THEIR INTERACTIONS. 
 
Table 1 shows the structure properties and docking statics of top 44 compounds. 
 
 
Sr.no. 
 
Name of compound 
 
Structure 
 
 
 
Source 
 
 
 
Mol. wt. 
 
Binding 
energy 
 
 
 
1. 
 
 
 
Flavan-3-ol 
 
 
 
 
 
 
 
Numerous    plant 
 
essential oil 
 
 
 
148.2065 
 
 
 
-7.1 
 
 
 
2. 
Flavan-4-ol  
 
 
 
 
 
 
 
 
Numerous    plant 
 
essential oil 
 
 
 
148.2065 
-6.8 
 
 
 
3. 
 
 
 
Terpenoid     isopentyl 
pyrophosphate 
 
 
 
 
 
 
 
 
Streptomyces 
 
species 
428.3993 -5.5 
 
 
 
4. 
 
 
 
Decyl-glcoside 
 
 
 
 
 
 
 
 
 
 
 
 
ORSELLINATE 
 
 
 
182.1777 
 
 
 
-6.1 
  
 
 
 
 
 
 
 
 
      
 
 
 
5. 
1-deoxy nojirimycin 
 
 
 
 
 
 
 
 
 
 
Cyanidin-3- 
galactoside 
 
 
 
182.1777 
 
 
 
-5.9 
 
 
 
6. 
 
Cyaniding-3- 
galactoside 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
182.1777 
 
 
 
-6.0 
 
 
 
7. 
 
 
Proanthrocyanidins 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jasminium      spp 
and Vicia faba 
 
 
 
212.19 
 
 
 
-5.8 
 
 
 
8. 
 
Demethoxycurcumin 
 
 
 
 
 
 
 
 
 
Persea spp 
 
turmeic 
 
 
 
338.35 
 
 
 
--6.1 
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a 
w 
 
s f 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
 
 
Bis- 
Demethoxycurc 
umin 
 
 
 
 
 
 
 
 
 
streptomyces tenebrarius, 
saccharomyces   porispora 
hiltus 
 
 
 
368.38 
 
 
 
-6.2 
 
1 
0 
 
 
 
3b-acetoxy- 
16b-hydroxy- 
butylinic acid 
 
 
 
 
 
 
 
 
 
 
From natural sources. 
 
 
 
224.21 
54 
 
 
 
- 5.6 
 
 
 
1 
1 
 
 
 
carvacrol 
 
 
 
 
 
 
 
 
catabolism of ornithine 
essential oil of Origanum 
vulgare, oil of thyme, oil 
obtained from pepperwort, wild 
bergamot 
 
 
 
150.217 
 
 
 
- 5.2 
 
 
 
1 
2 
 
 
 
ACARBOSE 
   
 
ctinoplanes spp 
 
 
 
645.605 
 
 
 
+20. 
82 
 
 
13 
. 
 
voglibose 
   
 
micromonospora species 
 
 
 
267.28 
 
-9.54 
 
 
14 
. 
 
miglitol 
   
 
honey & plant exudates 
excreted by the kidneys 
 
 
 
207.224 
 
 
 
-7.68 
 
 
15 
. 
 
 
linalool 
 idespread in nature 
Lauraceae, laurels,cinnamon, ro 
ewood, and Rutaceae, citrus 
ruits 
 
 
 
154.25 
 
 
 
- 5.4 
 
 
16 
. 
 
 
Beta-elemene 
 
 
 
 
 
 
 
widespread in plants and 
animals 
 
 
 
204.35 
 
 
 
-5.6 
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F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
. 
 
Beta- 
caryophyllene 
  
clove oil, the oil from the stems 
and flowers of Syzygium 
aromaticum(cloves) 
 
 
 
204.36 
 
 
 
-6.2 
 
 
18 
. 
 
Germacrene D 
  
plant species 
essential oil of the red 
deadnettle 
 
 
 
204.35 
 
 
 
-6.4 
 
 
19 
. 
 
 
Glutathione 
  
synthesized in the body from the 
amino acids L-cysteine, L- 
glutamic acid, andglycine 
 
307.32 
 
 
 
-6.2 
 
 
20 
. 
 
 
Chlorogenic 
acid 
  
Potatoes, bamboo, peach and 
prunes, green coffee bean 
extract 
 
 
 
354.31 
 
 
 
- 5.8 
 
 
21 
. 
 
 
Apigenin 
  
fruits and vegetables, 
but parsley, celery and chamomi 
le tea 
 
 
 
270.24 
 
 
 
- 6.0 
 
 
22 
. 
 
 
Naringenin 
  
grapefruits, oranges and 
tomatoes 
 
 
 
272.257 
 
 
 
-6.1 
 
 
23 
. 
 
 
Sergliflozin 
etabonate 
  
 
 
From plants 
 
 
 
448.463 
 
 
 
- 7.2 
 
 
24 
. 
 
 
Remogliflozin 
etabonate 
  
rom plants 
 
 
 
522.586 
 
 
 
-7.5 
 
 
35 
. 
 
 
 
Tofogliflozin 
  
From plants 
 
 
 
404.45 
 
 
 
- 7.6 
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clov 
bay 
 
 
M 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
. 
. 
 
26 
.       empagliflozin 
proximal 
tubules of nephronic component 
s in the kidneys 
 
450.91       
-7.0
 
 
 
 
27    canagliflozin                                                              
From natural plants 
 
444.52 
 
- 7.8 
 
 
 
28         dapagliflozin                                                         
From natural plants                              
408.873     
-7.7
 
 
 
pyridoxine                                                             Fish, soybeans, avocado, lima 
29                                                                                       beans, chicken, bananas, 
.                                                                                          cauliflower, green peppers 
 
169.18       
- 6.8
 
 
 
 
30          Apigenin                                                              parsley, celery and chamomile t 
.                                                                                          ea 
270.24 
-6.4 
 
 
 
 
31        Naringenin                                                              grapefruits, oranges and 
.                                                                                          tomatoes (skin) 
272.257     
- 6.6
 
 
 
 
 
33       Rosmarinic 
.                 acid 
mono- and dicotyledonous 
angiosperms 
360.31       
-7.1
 
 
 
 
Eugenol 
34 
. 
eoil, nutmeg,cinnamon,basil 
leaf 
 
 
164.20 
 
 
-6.4 
 
 
 
35     Oleanolic acid 
. 
Rosa                woodsii, Prosopis 
glandulosa, Hyptis capitata             456.70       -5.8 
 
 
 
 
 
36       Ursolic acid                                                                irabilis jalapa                               456.70       - 6.2 
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37 
. 
 
Valinol 
 
 
 
 
 
 
 
 
 
amino acid valine 
 
 
103.16 
 
-7.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7 
 
DISCUSSION 
27 | P a g e  
DISCUSSIONS: 
 
 
 
• Diabetes Mellitus disease is a common metabolic disorder leads to alteration of glucose 
concentration in blood because of inadequate insulin formation in the body or faulty cells 
which do not respond properly. The  symptom of Diabetes Mellitus generally appears in 
the age group 45-55 but now a days   any age group people can get this disease. The 
Diabetes pathological hallmarks consist of Alpha-Glucosidase enzyme which converts 
oligosaccharides to monosaccharides and hence there is an increase in glucose level in 
the blood. The drugs those are accessible for the treatments Diabetes Mellitus   have 
limitations like they have low usefulness and can cause diverse effects to eyes and heart. 
The  enzymes alpha-glucosidase is an effector target molecule because by blocking it we 
can get good inhibitors. 
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 8 CONCLUSIONS 
 
 
Diabetes   is a metabolic disease which affects the kidney,heart and other parts of the 
body. In diabetes body inslin production is inappropriate or cells do not respond to insulin 
properly. In this study  virtual screening of compound obtained from synthetic as well as natural 
product database is done by using docking study with Alpha Glucosidase concluded   that the 
compound having highest binding energy and bind to or near the active site can block the 
enzyme to bind with the substrate and can work as a potential inhibitors of alpha glucosidase  for 
 
the  treatment  of  Diabetes.    Docking  analysis  has  concluded  involvement  of  hydrogen  and 
 
hydrophobic interactions between the target enzyme and potential inhibitor molecule.. Finally 
 
based on the binding energy and toxicity study we have found Voglibose,Casuarine as best 
 
synthetic  drugs  and  Flavan-3-ol  to  be  the  top  natural  potential  inhibitors  against  alpha 
 
Glucosidase. 
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FUTURE WORK 
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 9 FUTURE WORKS 
 
 
 
 
 
In  the  current  state  of  Insilco,  each  work  is  first  checked  by  Insilco  designing  or  Virtual 
screening then invitro and invivo investigation is done. The future work of this Insilco study will 
be to do molecular dynamic simulation of the Alpha Glucosidase inhibitors compound to study 
their behavior in real system. In vitro and in vivo validation will be is must to propose the 
selected inhibitors as a potential drug candidate for inhibition of alpha glucosidase. 
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